Overview Zylet vs TobraDex in Blepharokeratoconjunctivitis Status: Completed Trial end date: 2007-06-01 Target enrollment: Participant gender: Summary The objective of this study is to evaluate the safety and efficacy of Zylet vs. Tobradex in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis Phase: Phase 4 Details Lead Sponsor: Bausch & Lomb IncorporatedTreatments: BB 1101DexamethasoneDexamethasone 21-phosphateDexamethasone acetateLoteprednol EtabonateTobramycin